Peptides / Immune and antimicrobial

Synthetic analog · 9 amino acids · 1,048.3 Da

Selepressin

Selepressin is an experimental vasopressin analog that acts on V1A receptors, studied for septic shock and not approved, and its phase 2b/3 trial stopped after finding no benefit. Studies in people tested it mostly on blood pressure and tracked side effects. PepBank shows 10 results on selepressin from 2 studies in people, and 53 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as FE 202158, FE-202158, FE202158

9 amino acids, from first to lastCFIXNCPXG

Evidence level: Mostly animal studies53 of 63 results come from studies in animals and lab cells. 2 studies in people.

Results in people

16% of 63 results

Results in animals

67% of 63 results

Results in lab cells

17% of 63 results

From computer models

0% of 63 results

Overview

Selepressin at a glance

What it is	Synthetic analog, 9 amino acids
Approval	Regulatory status not recorded
In sport	Status unknown
Studies	11 studies with results. All of them gave selepressin, with 63 results. 10 in people42 in animals11 in lab cells
Best study in people	Randomized controlled trial with 40 people (2017)
Clinical trials	3 registered: 0 active or planned, 3 with posted results

The science

What is selepressin?

A selective vasopressin V1A receptor agonist studied for septic shock.

Amino acids in one chain

The history of selepressin

2009November
A registered trial of selepressin started (NCT01000649).
2010
The oldest paper on selepressin in PepBank is from 2010.

Selepressin structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 9 amino acidsFrom the first amino acid to the last

C1FIXN5CPXG

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Selepressin is a synthetic analog of 9 amino acids, with a ring, 1 disulfide bond, 4 changed amino acids.

Formula

C₄₆H₇₃N₁₃O₁₁S₂

Molecular weight

1,048.3 g/mol

CAS number

876296-47-8

Target

AVPR1A (gene AVPR1A): full agonistEvidence: Primary functional reporter and binding assays establish selective human V1A receptor agonism.

Development

Ferring Pharmaceuticals. Highest phase: phase 3.

Identifiers

PubChem 53330936, ChEMBL CHEMBL1817709, UNII 8P2T76M0SJ, DrugBank DB12495, IUPHAR 11454

Full sequence, SMILES and InChIKey

Three-letter sequence
H-Cys-Phe-Ile-Hgn-Asn-Cys-Pro-Orn(iPr)-Gly-NH2

InChIKey
JCVQBJTWWDYUFQ-MRUTUVJXSA-N

SMILES
CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCCC(=O)N

See charge, composition and 3D structure on the Scientific page

The evidence

What selepressin studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Mostly animal studies53 of 63 results come from studies in animals and lab cells. 2 studies in people.

Heart and blood vessels

37 results · 5 in people · 26 animal · 6 lab

In septic shock, selepressin 2.5 ng/kg/minute maintained target blood pressure without norepinephrine in more patients than placebo. Critical care, 2017

Top results

In septic shock, selepressin 2.5 ng/kg/minute maintained target blood pressure without norepinephrine in more patients than placebo. (Critical care, 2017)
In sheep with septic shock, early selepressin maintained cardiac pumping better than arginine vasopressin. (Critical care medicine, 2016)
In sheep with septic shock, early selepressin slowed the blood lactate increase compared with arginine vasopressin. (Critical care medicine, 2016)

Lungs and breathing

5 results · 1 in people · 4 animal

In septic shock, selepressin 2.5 ng/kg/minute increased the proportion of days alive without ventilation compared with placebo. Critical care, 2017

Top results

In septic shock, selepressin 2.5 ng/kg/minute increased the proportion of days alive without ventilation compared with placebo. (Critical care, 2017)
In sheep with septic shock, early selepressin produced less lung fluid accumulation than arginine vasopressin. (Critical care medicine, 2016)
In sheep with septic shock, early selepressin produced less lung fluid accumulation than norepinephrine. (Critical care medicine, 2016)

Salt, water and minerals

3 results · 1 in people · 2 animal

In septic shock, fluid accumulation was lower from day 5 onward with selepressin 2.5 ng/kg/minute than placebo. Critical care, 2017

Top results

In septic shock, fluid accumulation was lower from day 5 onward with selepressin 2.5 ng/kg/minute than placebo. (Critical care, 2017)
In sheep with septic shock, early selepressin produced less fluid accumulation than arginine vasopressin. (Critical care medicine, 2016)
In sheep with septic shock, early selepressin produced less fluid accumulation than norepinephrine. (Critical care medicine, 2016)

Immune system and inflammation

4 results · 4 animal

In sheep with septic shock, early selepressin produced lower interleukin-6 levels than arginine vasopressin. Critical care medicine, 2016

Top results

In sheep with septic shock, early selepressin produced lower interleukin-6 levels than arginine vasopressin. (Critical care medicine, 2016)
In sheep with septic shock, early selepressin produced lower interleukin-6 levels than norepinephrine. (Critical care medicine, 2016)
In sheep with septic shock, early selepressin produced lower nitrite/nitrate levels than arginine vasopressin. (Critical care medicine, 2016)

Kidneys and bladder

1 result · 1 animal

In rats, FE 202158 lacked the urine-reducing activity seen with AVP at the tested dose. The Journal of pharmacology and experimental therapeutics, 2011

Top results

In rats, FE 202158 lacked the urine-reducing activity seen with AVP at the tested dose. (The Journal of pharmacology and experimental therapeutics, 2011)

Survival and serious illness

1 result · 1 animal

In sheep with septic shock, selepressin-treated animals lived longer than the other study animals. Critical care medicine, 2016

Top results

In sheep with septic shock, selepressin-treated animals lived longer than the other study animals. (Critical care medicine, 2016)

All 2 studies in people

In people

In septic shock, selepressin 2.5 ng/kg/minute maintained target blood pressure without norepinephrine in more patients than placebo.

2017Critical care40 people

In people

In worldwide safety reports, selepressin was not significantly linked to intestinal blood supply loss in the reporting analysis.

2022Frontiers in medicine

All 11 selepressin studies by area Open the Scientific page

Key selepressin studies

Studies in people come first, then studies in animals and in the lab.

People
Selepressin, a novel selective vasopressin V<sub>1A</sub> agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients
Russell et al. 2017 · Critical care (London, England) · 40 people · cited by 77
9 results
People
Vasopressors and Risk of Acute Mesenteric Ischemia: A Worldwide Pharmacovigilance Analysis and Comprehensive Literature Review
Jozwiak et al. 2022 · Frontiers in medicine · cited by 23
1 result
Animals
A Selective V(1A) Receptor Agonist, Selepressin, Is Superior to Arginine Vasopressin and to Norepinephrine in Ovine Septic Shock
He et al. 2016 · Critical care medicine · 46 subjects · cited by 64
19 results
Animals
Selepressin, a new V1A receptor agonist: hemodynamic comparison to vasopressin in dogs
Boucheix et al. 2013 · Shock (Augusta, Ga.) · 8 subjects · cited by 12
4 results
Animals
Unlike arginine vasopressin, the selective V1a receptor agonist FE 202158 does not cause procoagulant effects by releasing von Willebrand factor
Rehberg et al. 2012 · Critical care medicine · 6 subjects · cited by 14
2 results

All 11 Selepressin studies

Selepressin clinical trials

ClinicalTrials.gov lists 3 trials of selepressin. 0 are active or planned, and 3 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial

Phase 2/3terminated868 planned

Effects of the V1a Agonist FE 202158 in Patients With Septic Shock

Phase 2completed53 people

Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock

Phase 2completed31 people

Status and safety

Is selepressin approved?

FDA

United States

Status unknown

Status unknown.

EMA

European Union

Status unknown

Status unknown.

WADA

Sport

Not recorded

Status unknown.

Regulatory status not recorded. Status unknown.

Laws and labels change, so check the regulator for the current status.

Selepressin side effects and safety

PepBank has 17 safety results from studies of selepressin. 3 of them come from studies in people.

Safety results from studies (17)

In septic shock, adverse event frequency was similar with selepressin 2.5 ng/kg/minute and placebo. (Critical care, 2017)
In worldwide safety reports, selepressin was not significantly linked to intestinal blood supply loss in the reporting analysis. (Frontiers in medicine, 2022)
In septic shock, one of two patients receiving selepressin 3.75 ng/kg/minute stopped infusion for possible safety reasons. (Critical care, 2017)
In sheep, FE 202158 did not significantly change the clotting marker ratio compared with sham. (Critical care medicine, 2012)
In endotoxemic rabbits, selepressin reduced intestinal blood flow significantly less than arginine vasopressin. (Peptides, 2020)
In rabbits with and without early atherosclerosis, selepressin slightly increased blood pressure in a dose-dependent manner. (PloS one, 2016)
In sheep, FE 202158 produced a lower clotting marker ratio than arginine vasopressin. (Critical care medicine, 2012)
In endotoxemic rabbits, selepressin reduced blood supply to the stomach lining significantly less than arginine vasopressin. (Peptides, 2020)
In rabbits with and without endotoxemia, selepressin increased intestinal blood vessel resistance in a dose-dependent manner. (Peptides, 2020)
In rabbits, selepressin tended to increase intestinal blood vessel resistance less with endotoxemia than without it. (Peptides, 2020)
In rabbits with and without early atherosclerosis, selepressin moderately decreased heart rate. (PloS one, 2016)
In rabbits with and without early atherosclerosis, selepressin did not change the blood volume pumped per heartbeat. (PloS one, 2016)
In rabbits with and without early atherosclerosis, selepressin moderately decreased aortic blood flow. (PloS one, 2016)
In rabbits, selepressin blood pressure responses did not differ between animals with and without atherosclerosis. (PloS one, 2016)
In rabbits, selepressin heart rate responses did not differ between animals with and without atherosclerosis. (PloS one, 2016)
In rabbits, selepressin responses in blood volume per heartbeat did not differ between animals with and without atherosclerosis. (PloS one, 2016)
In rabbits, selepressin aortic blood flow responses did not differ between animals with and without atherosclerosis. (PloS one, 2016)

See every safety result on the Scientific page

Doses studied (6 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
2.5 ng/kg/minute	Human	human	infusion	Until shock resolution or a maximum of 7 days	Randomized trial in people · n = 40	Russell 2017
1.25 ng/kg/minute	Human	human	infusion	Until shock resolution or a maximum of 7 days	Randomized trial in people · n = 31	Russell 2017
3.75 ng/kg/minute	Human	human	infusion	Until shock resolution or a maximum of 7 days	Randomized trial in people · n = 2	Russell 2017
Initially 1 pmol/kg/min, then titrated	Animal	sheep	IV	Until death or maximum 30 hours	Study in live animals · n = 46	He 2016
1-300 ng · kg(-1) · min(-1)	Animal	dogs	infusion	Not reported	Study in live animals · n = 8	Boucheix 2013
10 pmol·kg(-1)·min(-1)	Animal	sheep	continuous intravenous infusion	120 minutes	Study in live animals · n = 6	Rehberg 2012

Questions and more

Ask a question about selepressin

The answer links to every study it uses.

What does the evidence say about selepressin?Is selepressin tested in people?Compare with Nangibotide Compare with Vasoactive intestinal peptide (VIP, aviptadil)

Sources

Database: PepBank data for selepressin (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about selepressin

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

Selepressin

Also known as FE 202158, FE-202158, FE202158

What it is

Synthetic analog, 9 amino acids

Approval

Regulatory status not recorded

In sport

Status unknown

Studies

11 studies with results. All of them gave selepressin, with 63 results.
10 in people42 in animals11 in lab cells

Best study in people

Randomized controlled trial with 40 people (2017)

Clinical trials

3 registered: 0 active or planned, 3 with posted results

Dose as reported

Class

Species

Route

Duration

Design

Source

2.5 ng/kg/minute

Human

human

infusion

Until shock resolution or a maximum of 7 days

Randomized trial in people · n = 40

Russell 2017

1.25 ng/kg/minute

Human

human

infusion

Until shock resolution or a maximum of 7 days

Randomized trial in people · n = 31

Russell 2017

3.75 ng/kg/minute

Human

human

infusion

Until shock resolution or a maximum of 7 days

Randomized trial in people · n = 2

Russell 2017

Initially 1 pmol/kg/min, then titrated

Animal

sheep

Until death or maximum 30 hours

Study in live animals · n = 46

He 2016

1-300 ng · kg(-1) · min(-1)

Animal

dogs

infusion

Not reported

Study in live animals · n = 8

Boucheix 2013

10 pmol·kg(-1)·min(-1)

Animal

sheep

continuous intravenous infusion

120 minutes

Study in live animals · n = 6

Rehberg 2012

Selepressin

Selepressin at a glance